Eli Lilly CEO David Ricks said during a J.P. Morgan Healthcare Conference that 2018 is the “time for action” to ease drug prices.
Ricks suggested the pharmaceutical industry could face consequences if it refuses to address drug prices, according to a Fierce Pharma report, which could muddy pharma’s scientific contributions.
“I think we have done some things that have been good, but we need to do more,” Ricks said. “If you look at where we are as an industry, there has never (been) a better time for science … that’s the good news.”
Ricks also commended Food and Drug Administration Commissioner Scott Gottlieb, saying recent moves have contributed to increased competition in the industry.